ALNEO included patients with potentially resectable disease and treated them with neoadjuvant alectinib for two cycles, ...

Adding an immune checkpoint inhibitor to neoadjuvant chemotherapy can improve pathologic complete response rates and may improve survival in patients with muscle-invasive bladder cancer, research ...

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

In this symposium, Frank Griesinger, Cecilia Pompili, and Jesme Fox discussed the latest evidence for neoadjuvant ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored ...

Our findings do not suggest high utilization of neoadjuvant chemotherapy is associated with a trade-off between perioperative and long-term outcomes,” the researchers wrote.

EMA committee recommends approval of BeOne Medicines’ Tevimbra to treat neoadjuvant/adjuvant NSCLC: San Carlos, California Wednesday, July 30, 2025, 12:00 Hrs [IST] BeOne Medici ...

Natera has announced the initiation of the Phase II TEODOR trial of its Signatera test aimed at replacing chemotherapy with ...

Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological respon ...

Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...